Image For Activity Cover
Beyond Socioeconomics and Access to Care: The Clinical Imperative for Understanding Racial HF Differences and Disparities
General Meeting Information
Despite improvements in medical and device therapy for HF, clinical outcomes for African-Americans with HF remain suboptimal. In order to understand the “why” for these persistent disparities, clinicians must be familiar with the multiple root causes. “Health disparities” according to the Institute of Medicine Report “Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare” are “differences[…]that are the result of the operation of healthcare systems, legal and regulatory climate as well as discriminatory biases, stereotyping and uncertainty.” In contrast to racial disparities, “Racial differences” should be defined as clinical, biological, genetic, or epigenetic factors associated with disease risk, outcome, or treatments not caused by social factors that vary in prevalence in population groups. It is imperative that clinicians understand both biologic differences and healthcare disparities to improve overall clinical outcomes for black patients with HF.
Learning Objectives
  • Discuss the persistent higher rates of HF hospitalization in AA with HF, limitations and impact of HRRP on minority-serving and safety-net hospitals.
  • Present the unique determinants and outcomes of HF in AA women, including PPCM, Adriamycin induced CMP - Describe the unique genetic and biologic determinants of HF in African Americans, including DCM, amyloid, and the new data that documents the limited utilization of genetic screening in patients of color.
  • Explain the poor underutilization of hydralazine-isosorbide dinitrate, and how this drug fits into the rapidly expanding landscape of novel therapies for HF (including ARNI, SGLT2i)
Availability: On-Demand
Expires on Sep 01, 2022
Cost : Member: $29.00
Non-Member: $45.00
Credit Offered:
1 CME Credit
1 MOC Point
Powered by Oasis.